Article Text

Download PDFPDF
The effect of introducing pelvic lymphadenectomy on survival and recurrence rates in Danish endometrial cancer patients at high risk: a Danish Gynecological Cancer Group study
  1. Gitte Ørtoft1,
  2. Claus Høgdall1,
  3. Caroline Juhl2,
  4. Lone K Petersen3,
  5. Estrid S Hansen4 and
  6. Margit Dueholm5
  1. 1 Department of Gynecology, Copenhagen University Hospital, Copenhagen, Denmark
  2. 2 Department of Gynecology and Obstetrics, Viborg Regional Hospital, Viborg, Denmark
  3. 3 Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark
  4. 4 Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark
  5. 5 Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark
  1. Correspondence to Gitte Ørtoft, Department of Gynecology, Copenhagen University Hospital, Copenhagen, Denmark; ortoft{at}


Objectives To evaluate the rate of survival and recurrence related to the introduction of pelvic lymphadenectomy in Danish high-risk endometrial cancer patients.

Study design Data on 713 high-risk patients defined as grade 3 with >50% myometrial invasion or serous/clear/undifferentiated carcinomas stage I–IV endometrial cancer patients diagnosed from 2005 to 2012 were retrieved from the Danish Gynecological Cancer Database. Of these, 305 were high-risk stage I. Five year Kaplan-Meier survival estimates and actuarial recurrence rates were calculated, and adjusted Cox used for comparison. Findings were compared with earlier Danish results.

Results Lymphadenectomy in 390 radically operated high-risk patients resulted in upstaging of 31 patients from stage I to IIIC and 19 patients from stage II to IIIC corresponding to 12.8%. Upstaging from stage I to IIIC had a cancer-specific survival of 77%, almost comparable to lymph node-negative high-risk stage I patients (81%). Lymphadenectomy patients had a significant higher overall survival as compared with non-lymph node resected for all patients, but not for stage I patients. Lymphadenectomy, however, did not significantly affect cancer-specific survival, progression-free survival, recurrence rate or risk of local, distant, or lymph node recurrence. When the survival of high-risk stage I patients was compared with earlier Danish results, a small improvement in overall survival (7%) and cancer-specificsurvival (8%) was demonstrated.

Conclusion Only a small number of high-risk patients were upstaged from stage I to III due to lymphadenectomy. These patients showed a surprisingly good survival possibly due to correct stage identification and subsequent relevant adjuvant therapy. However, even though introduction of lymphadenectomy in the Danish high-risk population seems to increase overall survival, no significant change in cancer-specific survival, progression-free survival or recurrence patterns was demonstrated.

View Full Text

Statistics from


  • Funding The study was financially supported by Health Research Fund of Central Denmark Region, Health Research Fund of Copenhagen University Hospital and Hans & Nora Buchards Fund.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.